Prognostic Value of LGE-CMR in HCM: A Meta-Analysis

JACC: Cardiovascular Imaging

Volumn 9, Issue 12, 2016, Pages 1392-1402

  Weng, Zhen ^a   Yao, Jialu ^b   Chan, Raymond H ^c   He, Jun ^a   Yang, Xiangjun ^b   Zhou, Yafeng ^b   He, Yang ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

cardiac magnetic resonance; hypertrophic cardiomyopathy; late gadolinium enhancement; meta analysis; myocardial fibrosis

Indexed keywords

GADOLINIUM; CONTRAST MEDIUM;

ADVERSE OUTCOME; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FOLLOW UP; HEART DEATH; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MEDLINE; META ANALYSIS; MORTALITY RATE; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RISK ASSESSMENT; RISK FACTOR; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; WEB OF SCIENCE; COMPLICATION; DEATH, SUDDEN, CARDIAC; DIAGNOSTIC IMAGING; FEMALE; MALE; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ODDS RATIO; PREDICTIVE VALUE; TIME FACTOR;

CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; FEMALE; GADOLINIUM; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 85001104629     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2016.02.031     Document Type: Article

References (25)

1. 1 Klarich, K.W., Attenhofer Jost, C.H., Binder, J., et al. Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol 111 (2013), 1784–1791.
2. 2 Semsarian, C., Ingles, J., Maron, M.S., Maron, B.J., New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 65 (2015), 1249–1254.
3. 3 Maron, B.J., Maron, M.S., Hypertrophic cardiomyopathy. Lancet 381 (2013), 242–255.
4. 4 Maron, B.J., Spirito, P., Shen, W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298 (2007), 405–412.
5. 5 Maron, B.J., Spirito, P., Ackerman, M.J., et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 61 (2013), 1527–1535.
6. 6 Maron, M.S., Maron, B.J., Harrigan, C., et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 54 (2009), 220–228.
7. 7 Pennell, D.J., Cardiovascular magnetic resonance. Circulation 121 (2010), 692–705.
8. 8 Reichek, N., Gupta, D., Hypertrophic cardiomyopathy: cardiac magnetic resonance imaging changes the paradigm. J Am Coll Cardiol 52 (2008), 567–568.
9. 9 Maron, M.S., Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magnet Reson, 14, 2012, 13.
10. 10 Green, J.J., Berger, J.S., Kramer, C.M., Salerno, M., Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Img 5 (2012), 370–377.
11. 11 Chan, R.H., Maron, B.J., Olivotto, I., et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130 (2014), 484–495.
12. 12 Hen, Y., Iguchi, N., Utanohara, Y., et al. Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circ J 78 (2014), 929–937.
13. 13 Ismail, T.F., Jabbour, A., Gulati, A., et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart 100 (2014), 1851–1858.
14. 14 Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed July 1, 2016.
15. 15 Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
16. 16 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
17. 17 Maron, M.S., Appelbaum, E., Harrigan, C.J., et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 1 (2008), 184–191.
18. 18 O'Hanlon, R., Grasso, A., Roughton, M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 56 (2010), 867–874.
19. 19 Bruder, O., Wagner, A., Jensen, C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56 (2010), 875–887.
20. 20 Rubinshtein, R., Glockner, J.F., Ommen, S.R., et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 3 (2010), 51–58.
21. 21 Briasoulis, A., Mallikethi-Reddy, S., Palla, M., Alesh, I., Afonso, L., Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart 101 (2015), 1406–1411.
22. 22 Elliott, P.M., Anastasakis, A., Borger, M.A., et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 (2014), 2733–2779.
23. 23 Wagner, A., Bruder, O., Schneider, S., et al. Current variables, definitions and endpoints of the European cardiovascular magnetic resonance registry. J Cardiovasc Magn Res, 11, 2009, 43.
24. 24 Kuribayashi, T., Roberts, W.C., Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 70 (1992), 1333–1340.
25. 25 Chan, R.H., Maron, B.J., Olivotto, I., et al. Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol 116 (2015), 436–441.